Email: ielsg@ior.usi.ch /
Phone: + 41 58 666 73 04/05/06
LATEST NEWS
- IELSG Studies presented during 17-ICML
Oral presentations
IELSG37 – A randomized trial of observation versus radiotherapy in primary mediastinal B-cell lymphoma patients with complete metabolic response after standard immunochemotherapy
IELSG39 – The IELSG39 trial: efficacy of first-line chlamydia psitaci eradication with a six-month regimen of doxycycline in patients with stage-I MALT lymphoma of ocular adnexae
IELSG43 – Consolidative HCT-ASCT is superior to non-myeloablative chemo-immuotherapy in newly-diagnosed PCNSL – Updated results of the randomized phase IIMATRix/IELSG43 trial
IELSG47 – Rituximab and ibrutinib combination is safe and effective in untreated splenic and nodal marginal zone lymphomas: planned subset analysis of the IESLG47/MALIBU phase II studyPoster presentation
IELSG35 – Primary lymphoma of the female genital tract: a retrospective survey of the International Extranodal Lymphoma Study Group - IELSG Annual Meeting 2024
The next Annual Meeting of the International Extranodal Lymphoma Study Group (IELSG) will be held on March 8-9, 2024 in Stresa (Italy) at Hotel La Palma.
More information will follow soon.
ONGOING STUDIES
- IELSG50IELSG50 Pembrolizumab and radiotherapy for previously untreated patients with limited-stage NK/T cell lymphoma who are not eligible for chemotherapy Participants required: 30… Read more: IELSG50
- IELSG44IELSG44 FDG-PET evaluation for marginal zone lymphoma and its prognostic role: an international multicenter retrospective analysis (PIMENTO) Participants required: 350 Investigator responsible(s):… Read more: IELSG44
- IELSG45 StudyRandomized phase II trial on fitness- and comorbidity- tailored treatment in elderly patients with newly diagnosed primary CNS lymphoma (FIORELLA Trial)
LATEST NEWSLETTER
- Newsletter Number 53
Click here to open the pdf file – Click here to read the newsletter in HTML
- Newsletter Number 52
PUBLICATIONS
- IELSG40/CLEO phase II trial of clarithromycin and lenalidomide in relapsed/refractory extranodal marginal zone lymphomaReference IELSG40/CLEO phase II trial of clarithromycin and lenalidomide in relapsed/refractory extranodal marginal zone lymphoma. Link Author(s) Pirosa MC, Sassone M, Kiesewetter B, Guillermo AL, Devizzi L, Domènech ED, Tucci A, Mannina D, Merli M, Salar… Read more: IELSG40/CLEO phase II trial of clarithromycin and lenalidomide in relapsed/refractory extranodal marginal zone lymphoma
- Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trialReference Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. Link Author(s) Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E,… Read more: Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial